Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
BO-112 by Highlight Therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma): Likelihood of Approval
BO-112 is under clinical development by Highlight Therapeutics and currently in Phase II for Basal Cell Carcinoma (Basal Cell Epithelioma)....
Data Insights
BO-112 by Highlight Therapeutics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
BO-112 is under clinical development by Highlight Therapeutics and currently in Phase I for Head And Neck Squamous Cell Carcinoma...